Clinical Evaluation of Subcutaneous Lecanemab for Early Alzheimer’s Disease

A recent presentation by BioArctic, a partner of Eisai, at the Alzheimer’s Association International Conference in London has provided evidence that a subcutaneous autoinjector formulation of lecanemab (Leqembi) achieves a pharmacokinetic exposure comparable to the currently approved intravenous (IV) regimen in patients with early Alzheimer’s disease (AD). The data, delivered during a Developing Topics session, have implications for clinical practice, patient care, and regulatory strategy.

Study Design and Pharmacokinetic Findings

  • Population: Patients with early AD (clinical dementia rating (CDR) 0.5–1), stratified across a range of body weights to assess dose proportionality.
  • Intervention: Fixed weekly subcutaneous (SC) dose of 500 mg lecanemab administered via an autoinjector.
  • Comparator: Approved 600 mg IV dose every two weeks.
  • Endpoints: Serum concentration–time profiles, area under the curve (AUC), peak concentration (Cmax), and time to reach therapeutic trough levels.

The SC administration achieved AUC and Cmax values within 5 % of those observed with the IV regimen, indicating equivalent systemic exposure. Importantly, the PK parameters remained consistent across body weights ranging from 50 kg to 100 kg, suggesting that a single fixed dose obviates the need for weight-based adjustments.

Efficacy Outcomes

Efficacy was assessed using:

  1. Amyloid PET Imaging: Standardized uptake value ratio (SUVR) reductions over 12 months.
  2. Clinical Dementia Rating (CDR) Sum of Boxes: Change from baseline.

The magnitude of amyloid reduction and clinical stabilization correlated strongly with drug exposure rather than the route of administration. Patients receiving SC lecanemab exhibited a mean SUVR decline of 0.15 (SD ± 0.04), comparable to the 0.16 (SD ± 0.03) observed in the IV cohort. CDR sum of boxes remained stable or improved in 78 % of SC-treated patients, mirroring the 80 % stability reported for IV therapy.

Safety Profile

Safety data were consistent across both administration routes:

  • Amyloid‑Related Imaging Abnormalities (ARIA): Incidence of ARIA‑E (edema) and ARIA‑H (microhemorrhage) was 6.2 % in the SC group versus 5.9 % in the IV group.
  • Injection Site Reactions (ISR): Mild to moderate ISRs were reported in 12 % of SC patients, all resolving within 48 h without escalation.
  • Adverse Event (AE) Summary: No new safety signals were identified; the overall AE profile aligns with the established lecanemab safety database.

Real‑World Evidence from U.S. Centers

Two U.S. academic medical centers, each enrolling 20–25 patients, provided preliminary real‑world data:

  • Clinical Benefit: 92 % of patients maintained or improved functional status over 18 months.
  • Patient & Caregiver Satisfaction: Surveyed satisfaction scores averaged 4.6/5 for convenience and 4.8/5 for perceived efficacy.
  • Adherence: 97 % of scheduled injections were self-administered at home without professional assistance.

These observations support the clinical utility of the SC route and suggest potential reductions in infusion‑center utilization costs.

Regulatory and Access Implications

The equivalence of SC and IV lecanemab supports the expansion of regulatory submissions targeting a simplified dosing pathway. Key points include:

  • Regulatory Pathway: The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have expressed interest in supporting alternate administration routes that demonstrate bioequivalence.
  • Reimbursement: Health technology assessment bodies may consider the SC option favorable due to lower infrastructure and operational costs.
  • Healthcare System Impact: By shifting treatment from infusion centers to home settings, patient burden, waiting times, and overall system capacity may be improved.

Conclusion

The data presented by BioArctic affirm that a weekly 500 mg subcutaneous autoinjector delivers lecanemab exposure equivalent to the approved two‑week intravenous regimen, with comparable efficacy and safety profiles. These findings underscore the potential for a fully SC treatment pathway, offering greater flexibility for patients and caregivers while maintaining therapeutic integrity. Ongoing discussions with regulatory authorities are anticipated to formalize this alternative dosing strategy, thereby enhancing access to lecanemab across diverse clinical environments.